SLS-007 is a Peptide-based Approach Targeting the NACore for Parkinson’s Disease
- SLS-007 is a family of rationally-designed peptidic inhibitors which target the NACore (non-amyloid component core) of alpha-synuclein (α-synuclein) to inhibit protein aggregation in patients with Parkinson's Disease (PD)
- The overexpression of α-synuclein leads to the formation of α-synuclein aggregates which comprise Lewy bodies and neurites which are the hallmarks of the pathogenesis of PD
- Recent in vitro and cell culture research have shown that SLS-007 has the potential to stop the propagation and seeding of α-synuclein aggregates
- Seelos will evaluate in vivo delivery of SLS-007 in a PD transgenic mouse model
- The goal will be to establish the in vivo pharmacokinetics and pharmacodynamics profile and target engagement parameters of SLS-007
- The α-synuclein protein function in the healthy brain is currently unknown
- It is of great interest to PD researchers because it is a major constituent of Lewy bodies, protein clumps that are the pathological hallmark of PD
- In the several years since its discovery, α-synuclein has been the focus of intensive efforts by basic PD researchers working to definitively characterize the protein's role in PD and its potential as a target for neuroprotective therapies
SLS-007: α-synuclein as a Therapeutic Target
- Stoker TB, Torsney KM, Barker RA. Emerging treatment approaches for Parkinson’s Disease. Front Neurosci. 2018; 12:693.
2. Brundin P, Dave KD, Kordower. Therapeutic approaches to target alpha-synuclein pathology. Experimental Neurology. 2017;298:225-235.